PET/MR: A paradigm shift

Cancer Imaging

Volumn 13, Issue 1, 2013, Pages 36-52

  Gaertner, Florian C ^a   Furst, Sebastian ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cardiology; Magnetic resonance tomography; Neurology; Oncology; PET MR; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; GADOTERIC ACID; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

BONE INFECTION; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CHRONIC OSTEOMYELITIS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORONARY ARTERY DISEASE; ECHOGRAPHY; ENTERITIS; GRAFT INFECTION; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MAMMOGRAPHY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIATION ATTENUATION; RADIATION EXPOSURE; RADIATION SAFETY; RADIOFREQUENCY; REVIEW; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; STANDARDIZATION; VASCULITIS; VELOCITY;

CORONARY ARTERY DISEASE; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NERVOUS SYSTEM DISEASES; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY;

EID: 84875532593     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2013.0005     Document Type: Review

References (55)

1. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000; 41: 1369-1379. PMid:10945530. (Pubitemid 30643379)
2. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007; 48(Suppl 1): 78S-88S. PMid:17204723. (Pubitemid 47604945)
3. Wechalekar K, Sharma B, Cook G. PET/CT in oncology-a major advance. Clin Radiol 2005; 60: 1143-1155. doi:10.1016/ j.crad.2005.05.018. PMid:16223611.
4. Picchio M, Mansueto M, Crivellaro C, et al. PET/CT and contrast enhanced CT in single vs. two separate sessions: a cost analysis study. Q J Nucl Med Mol Imaging 2012; 56: 309-316. PMid:22510702.
5. Townsend DW. Combined positron emission tomography-computed tomography: the historical perspective. Semin Ultrasound CT MR 2008; 29: 232-235. doi:10.1053/j.sult.2008.05.006. PMid:18795489.
6. Delso G, Ziegler S. PET/MRI system design. Eur J Nucl Med Mol Imaging 2009; 36(Suppl 1): S86-S92. doi:10.1007/s00259- 008-1008-6. PMid:19104809.
7. von Schulthess GK, Burger C. Integrating imaging modalities: what makes sense from a workflow perspective? Eur J Nucl Med Mol Imaging 2010; 37: 980-990. doi:10.1007/s00259-009- 1378-4. PMid:20140613.
8. Shao Y, Cherry SR, Farahani K, et al. Simultaneous PET and MR imaging. Phys Med Biol 1997; 42: 1965-1970. doi:10.1088/0031- 9155/42/10/010. PMid:9364592. (Pubitemid 27448997)
9. Pichler BJ, Judenhofer MS, Catana C, et al. Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med 2006; 47: 639-647. PMid:16595498. (Pubitemid 46768465)
10. Delso G, Furst S, Jakoby B, et al. Performance measurements of the Siemens mMR integrated whole-body PET/MR scanner. J Nucl Med 2011; 52: 1914-1922. doi:10.2967/ jnumed.111.092726. PMid:22080447.
11. Drzezga A, Souvatzoglou M, Eiber M, et al. First clinical experience with integrated whole-body PET/MR. Comparison to PET/ CT in patients with oncologic diagnoses. J Nucl Med 2012; 53: 845-855. doi:10.2967/jnumed.111.098608. PMid:22534830.
12. Kinahan PE, Hasegawa BH, Beyer T. X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med 2003; 33: 166-179. PMid:12931319. (Pubitemid 36859496)
13. Hofmann M, Pichler B, Scholkopf B, Beyer T. Towards quantitative PET/MRI: a review of MR-based attenuation correction techniques. Eur J Nucl Med Mol Imaging 2009; 36(Suppl 1): S93-S104. doi:10.1007/s00259-008-1007-7. PMid:19104810.
14. Martinez-Moller A, Souvatzoglou M, Delso G, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med 2009; 50: 520-526. doi:10.2967/jnumed. 108.054726. PMid:19289430.
15. Martinez-Moeller A, Souvatzoglou M, Navab N, Schwaiger M, Nekolla SG. MR-based attenuation correction for whole-body MR/PET. J Nucl Med 2008; 49(Suppl 1): 65.
16. Berker Y, Franke J, Salomon A, et al. MRI-based attenuation correction for hybrid PET/MRI systems: a 4-class tissue segmentation technique using a combined ultrashort-echo-time/Dixon MRI sequence. J Nucl Med 2012; 53: 796-804. doi:10.2967/ jnumed.111.092577. PMid:22505568.
17. Townsend DW, Carney JP, Yap JT, Hall NC. PET/CT today and tomorrow. J Nucl Med 2004; 45(Suppl 1): 4S-14S. PMid:14736831.
18. Eiber M, Martinez-Moller A, Souvatzoglou M, et al. Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. Eur J Nucl Med Mol Imaging 2011; 38: 1691-1701. doi:10.1007/s00259- 011-1842-9. PMid:21688050.
19. Brix G, Nekolla EA, Nosske D, Griebel J. Risks and safety aspects related to PET/MR examinations. Eur J Nucl Med Mol Imaging 2009; 36(Suppl 1): S131-S138. doi:10.1007/s00259- 008-0937-4. PMid:19104806.
20. International Commission on Non-Ionizing Radiation Protection. Medical magnetic resonance (MR) procedures: protection of patients. Health Phys 2004; 87: 197-216. doi:10.1097/ 00004032-200408000-00008. PMid:15257220.
21. Thomsen HS. Recent hot topics in contrast media. Eur Radiol 2011; 21: 492-495. doi:10.1007/s00330-010-2026-x. PMid:- 21136062.
22. Hasebroock KM, Serkova NJ. Toxicity of MRI and CT contrast agents. Expert Opin Drug Metab Toxicol 2009; 5: 403-416. doi:10.1517/17425250902873796. PMid:19368492.
23. Brooks RA. A quantitative theory of the Hounsfield unit and its application to dual energy scanning. J Comput Assist Tomogr 1977; 1: 487-493. doi:10.1097/00004728-197710000-00016. PMid:615229. (Pubitemid 8228115)
24. Wehrl HF, Judenhofer MS, Wiehr S, Pichler BJ. Pre-clinical PET/ MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging 2009; 36(Suppl 1): S56-S68. doi:10.1007/s00259-009-1078-0. PMid:19194703.
25. Gaertner FC, Souvatzoglou M, Brix G, Beer AJ. Imaging of hypoxia using PET and MRI. Curr Pharm Biotechnol 2012; 13: 552-570. doi:10.2174/ 138920112799436267. PMid:22214501.
26. Antoch G, Bockisch A. Combined PET/MRI: a new dimension in whole-body oncology imaging? Eur J Nucl Med Mol Imaging 2009; 36(Suppl 1): S113-S120. doi:10.1007/s00259-008-0951-6. PMid:19104802.
27. Van Goethem M, Tjalma W, Schelfout K, Verslegers I, Biltjes I, Parizel P. Magnetic resonance imaging in breast cancer. Eur J Surg Oncol 2006; 32: 901-910. doi:10.1016/j.ejso.2006.06.009. PMid:16920327. (Pubitemid 44636925)
28. Heusner TA, Kuemmel S, Umutlu L, et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 2008; 49: 1215-1222. doi:10.2967/jnumed.108.052050. PMid:18632831.
29. Souvatzoglou M, Gaertner FC, Schwarzenboeck S, Beer AJ, Schwaiger M, Krause BJ. PET/CT for the diagnosis, staging & restaging of prostate cancer. Imaging Med 2011; 3: 571-585. doi:10.2217/iim.11.48.
30. Beer AJ, Eiber M, Souvatzoglou M, Schwaiger M, Krause BJ. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol 2011; 12: 181-191. doi:10.1016/S1470- 2045(10)70103-0. PMid:20599424.
31. Collins CD. PET/CT in oncology: for which tumours is it the reference standard? Cancer Imaging 2007; 7(A): S77-S87. (Pubitemid 350200309)
32. Wu LM, Xu JR, Gu HY, et al. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better? J Surg Res 2012; 178: 304-314. doi:10.1016/ j.jss.2012.03.074. PMid:22541065.
33. Pauls S, Schmidt SA, Juchems MS, et al. Diffusion-weighted MR imaging in comparison to integrated [18F]-FDG PET/CT for Nstaging in patients with lung cancer. Eur J Radiol 2012 81 178-182 doi:10.1016/j.ejrad.2010.09.001. PMid 20932700.
34. Saksena MA, Saokar A, Harisinghani MG. Lymphotropic nanoparticle enhanced MR imaging (LNMRI) technique for lymph node imaging. Eur J Radiol 2006; 58: 367-374. doi:10.1016/ j.ejrad.2005.12.041. PMid:16472955. (Pubitemid 43729065)
35. Schmidt GP, Schoenberg SO, Schmid R, et al. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 2007; 17: 939-949. doi:10.1007/s00330-006-0361-8. PMid:16951929. (Pubitemid 46766875)
36. Coenegrachts K, De Geeter F, ter Beek L, et al. Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDGPET/ CT for the detection of colorectal liver metastases. Eur Radiol 2009; 19: 370-379. doi:10.1007/s00330- 008-1163-y. PMid:18795299.
37. Dikaios N, Izquierdo-Garcia D, Graves MJ, Mani V, Fayad ZA, Fryer TD. MRI-based motion correction of thoracic PET: initial comparison of acquisition protocols and correction strategies suitable for simultaneous PET/MRI systems. Eur Radiol 2012; 22: 439-446. doi:10.1007/s00330-011-2274-4. PMid:- 21938440.
38. Klasner BD, Krause BJ, Beer AJ, Drzezga A. PET imaging of gliomas using novel tracers: a sleeping beauty waiting to be kissed. Expert Rev Anticancer Ther 2010; 10: 609-613. doi:10.1586/ era.10.37. PMid:20469990.
39. Herholz K. PET studies in dementia. Ann Nucl Med 2003; 17: 79-89. doi:10.1007/BF02988444. PMid:12790355. (Pubitemid 36693059)
40. Koepp MJ, Woermann FG. Imaging structure and function in refractory focal epilepsy. Lancet Neurol 2005; 4: 42-53. doi:10.1016/S1474-4422(04)00965-2. PMid:15620856. (Pubitemid 40023235)
41. Heiss WD. The potential of PET/MR for brain imaging. Eur J Nucl Med Mol Imaging 2009; 36(Suppl 1): S105-S112. doi:10.1007/s00259-008-0962-3. PMid:19104801.
42. Nekolla SG, Martinez-Moeller A, Saraste A. PET and MRI in cardiac imaging: from validation studies to integrated applications. Eur J Nucl Med Mol Imaging 2009; 36(Suppl 1): S121-S130. doi:10.1007/s00259-008-0980-1. PMid:19104798.
43. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003; 42: 1318-1333. doi:10.1016/j.jacc.2003.08.011. PMid:14522503. (Pubitemid 37188362)
44. Martinez-Moller A, Souvatzoglou M, Navab N, Schwaiger M, Nekolla SG. Artifacts from misaligned CT in cardiac perfusion PET/CT studies: frequency, effects, and potential solutions. J Nucl Med 2007; 48: 188-193. PMid:17268013. (Pubitemid 47555342)
45. Gotthardt M, Bleeker-Rovers CP, Boerman OC, Oyen WJ. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med 2010; 51: 1937-1949. doi:10.2967/jnumed.110.076232. PMid:21078798.
46. Termaat MF, Raijmakers PG, Scholten HJ, Bakker FC, Patka P, Haarman HJ. The accuracy of diagnostic imaging for the assessment of chronic osteomyelitis: a systematic review and meta-analysis. J Bone Joint Surg Am 2005; 87: 2464-2471. doi:10.2106/ JBJS.D.02691. PMid:16264122. (Pubitemid 41546377)
47. Gratz S, Dorner J, Fischer U, et al. 18F-FDG hybrid PET in patients with suspected spondylitis. Eur J Nucl Med Mol Imaging 2002; 29: 516-524. PMid:11914890.
48. Nawaz A, Torigian DA, Siegelman ES, Basu S, Chryssikos T, Alavi A. Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. Mol Imaging Biol 2010; 12: 335-342. doi:10.1007/ s11307-009-0268-2. PMid:19816744.
49. Glaudemans AW, Quintero AM, Signore A. PET/MRI in infectious and inflammatory diseases: will it be a useful improvement? Eur J Nucl Med Mol Imaging 2012; 39: 745-749. doi:10.1007/ s00259-012-2060-9. PMid:22297458.
50. Treglia G, Focacci C, Caldarella C, et al. The role of nuclear medicine in the diagnosis of spondylodiscitis. Eur Rev Med Pharmacol Sci 2012; 16(Suppl 2): 20-25. PMid:22655480.
51. Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 2006; 55: 131-137. doi:10.1002/art.21699. PMid:16463425. (Pubitemid 43235138)
52. Hautzel H, Sander O, Heinzel A, Schneider M, Muller HW. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio. J Nucl Med 2008; 49: 1107-1113. doi:10.2967/ jnumed.108.051920. PMid:18552151. (Pubitemid 351948019)
53. Spacek M, Belohlavek O, Votrubova J, Sebesta P, Stadler P. Diagnostics of -non-acute- vascular prosthesis infection using 18F-FDG PET/CT: our experience with 96 prostheses. Eur J Nucl Med Mol Imaging 2009; 36: 850-858. doi:10.1007/ s00259-008-1002-z. PMid:19107480.
54. Bleeker-Rovers CP, Vos FJ, Corstens FH, Oyen WJ. Imaging of infectious diseases using [18F] fluorodeoxyglucose PET. Q J Nucl Med Mol Imaging 2008; 52: 17-29. PMid:17657204. (Pubitemid 351351041)
55. Martinez-Moller A, Eiber M, Nekolla SG, et al. Workflow and scan protocol considerations for integrated whole-body PET/MRI in oncology. J Nucl Med 2012; 3: 1415-1426.